(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Gender-affirming care happens not only with medications but with communication, curiosity, and respect,” Boos said.

Toothpaste is being touted on social media as a hack to clear acne, soothe burns and whiten fingernails. But dermatologists ...

Researchers conducted a post hoc analysis to evaluate incidence, severity, and time to first onset of rash and paronychia in patients with lung cancer treated with amivantamab. Rash, paronychia, and ...

But now those lines keep on keeping on-even when we're frowning at them! Thankfully, there's many crow's feet remedies that ...

Facial hair in women can be distressing. It can be caused by several factors or conditions. Medications, procedures and weight loss can help.

BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized ...

Abstract entitled, “Safety and Efficacy of Synchronous Ultrasound Parallel Beam Technology to Lift the Upper Lip and Improve ...

The degree of improvement was impressive and not far off from those reported with CO2 ablative laser,” Luke Horton, MD, said.

BOULDER, CO / ACCESSWIRE / October 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized ...

New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) ...

First results from the phase III READY-4 trial demonstrate the long-term safety of repeated injections of RelabotulinumtoxinA for both frown lines and ...